Drug Approval | December 04, 2025
FDA nod to priority review to AstraZeneca’s Baxdrostat for hard-to-control hypertension
Here's a development that aims to keep your blood pressure in check. Literally!
Here's a development that aims to keep your blood pressure in check. Literally!
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
Angelini Ventures has already invested €125 million in 22 startups
LYMPHIR addresses a clear clinical need in a disease with limited treatment options
The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025
The deal aims to address long-standing imbalances in pharmaceutical trade while boosting investment and innovation on both sides of the Atlantic
Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN
This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA
Phase one of the expansion will convert an existing hall into an ISO 7-certified cleanroom for GMP-compliant production
StarGuide GX delivers ultra-high sensitivity and high-resolution imaging, enabling fast, confident diagnostics
Subscribe To Our Newsletter & Stay Updated
